The size of the nuclear medicine market in the Asia Pacific is estimated at USD 2.29 billion in 2021 and is poised to reach USD 4.39 billion by 2026, at a CAGR of 13.9%.
The increase in chronic diseases such as cancer, cardiovascular diseases, and targeted conditions is driving the nuclear medicine market. Also, due to the growing demand for effective treatment and diagnostics procedures, market growth is expected further. In addition, an increase in advancements of the technology for developing and improving the treatment and medication procedures for treating the diseases is expected to provide lucrative growth opportunities to the market growth.
On the other hand, raising awareness among the people about pre-diagnosing the diseases and the availability of the treatment in the market is expected to increase the demand for nuclear medicine. Furthermore, the growing population is considered one of the significant growth influential factors of the nuclear medicine market. The increasing senior population is more prone to various chronic diseases such as cancer and other cardiovascular diseases. India and China have the largest population globally, and Japan holds the largest share of older people in this region.
Rising competition among the players is due to a rise in pricing as well as the presence of various types of products available in the market, which is pressuring them to acquire multiple marketing strategies such as developing or improving the development, collaboration, and acquisition to maintain their position in the market this is likely to drive the demand for nuclear medicine. Furthermore, the rise in the initiative and investment from government and non-government firms for research purpose activities for developing new innovative techniques encourage market growth.
However, the lack of skilled and trained individuals for performing diagnostic procedures and operating the equipment are the other factors that hamper the growth of the nuclear medicine market. The high cost of the equipment used for diagnosing and therapeutic procedures is the primary factor impeding the market growth. Furthermore, the new product approval procedure and strict government rules and regulations make new product entry more complex. The approval processes are time-consuming and laborious, limiting the growth of the nuclear medicine market in the APAC region.
This research report on the Asia Pacific nuclear medicine market has been segmented and sub-segmented into the following categories:
Geographically, the Asia Pacific nuclear medicine market is expected to grow at the fastest rate during the forecast period and is primarily driven by the increasing number of cardiovascular diseases and cancer cases, improving the healthcare sector, and favorable reimbursement policies. As nuclear medicine is beneficial in treating cardiovascular diseases and cancer, the market is expected to grow with the increasing number of cardiovascular cases and cancer cases across emerging countries such as China, Japan, and India. In addition, other factors such as the availability of labor at low cost and substantial generic market increased government spending on Research and development in developing countries and the shifting focus of prominent market players from developed Nations to developing countries such as China, Japan, and India.
China held a significant share in the APAC market in 2020 and is expected to retain a significant share in the market during the forecast period. The major factors driving the market are the government policies facilitating the growth of the research and development sector, which helps develop new drugs and technological advancements. Also, well-established healthcare facilities and the availability of low-cost labor and raw materials at low cost have resulted in the market's growth.
On the other hand, India is also expected to grow exponentially due to the increased Healthcare spending and the government policies in favor of the companies. In addition, the availability of labor at low cost is also helping India emerge as a manufacturing hub for many pharmaceutical companies focusing on nuclear medicine.
Japan is also emerging as a potential market in recent years due to the government's technological advancement and shifting focus on Research and development.
KEY MARKET PLAYERS:
A few of the noteworthy companies operating in the APAC Nuclear Medicine Market are Cardinal Health, Inc., Bracco Imaging S.p.A, GE Healthcare, Eczacibasi-Monrol Nuclear Products, Nordion, Inc., Bayer Healthcare, Lantheus Medical Imaging, Inc., Advanced Accelerator Applications S.A., IBA Molecular Imaging, Mallinckrodt plc.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.2 Analysis Design
2.3 Research Phases
2.3.1 Secondary Research
2.3.2 Primary Research
2.3.3 Econometric Modelling
2.3.4 Expert Validation
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 By Type
5.2 By Application
6.5 South Korea
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 GE Healthcare
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Cardinal Health Inc.
8.3 Bracco Imaging S.p.A
8.4 Eczacibasi-Monrol Nuclear Products
8.5 Nordion, Inc.
8.6 Bayer Healthcare
8.7 Lantheus Medical Imaging, Inc.
8.8 Advanced Accelerator Applications S.A.
8.9 IBA Molecular Imaging
8.10 Mallinckrodt plc.
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities